JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v4i4.1378Articlehttps://artdesignp.com/journal/JCNR/4/4/10.26689/jcnr.v4i4.1378FengJia,WangShujin,ZuoHong,LiuXufeng,LiGuohong,YuNiu2020442020-07-28Objective: To investigate the peroxisome proliferator-activated receptor-? (peroxisome) in patients with type 2 diabetes mellitus. Proliferators-activated receptors-?, PPARs-? (?) gene polymorphisms about serum lipofuscin and leptin. Methods: One hundred and twenty patients with type 2 diabetes admitted to our hospital from June 2015 to June 2018 were selected. The patients were divided into an obese group and a non-obese group of 60 patients each according to their waist circumference. A polymerase chain reaction-length polymorphism protocol was implemented in all patients to explore the PPAR-? gene polymorphism, and blood glucose, lipid, adiponectin and leptin levels were measured in both groups. Results: PPAR-? gene polymorphisms in type 2 diabetic patients were dominated by wild-type homozygous; The levels of total cholesterol, triglyceride and LDL cholesterol in the obese group were significantly higher than those in the non-obese group, while the levels of HDL cholesterol were lower than those in the non-obese group. There is significant difference in comparison between groups (P<0.05) Those carrying the A allele had a significant lipid disorder profile and decreased adiponectin levels. Conclusions: PPAR-? gene polymorphisms in type 2 diabetes are not significantly associated with adiponectin and leptin, and only in the obese group, the patients with the Allele A showed significant dyslipidemia and a declining trend of adiponectin levels.